基于氧化还原敏感的喜树碱-阿糖胞苷偶联物组装的新型自递药系统的合理设计用于有效协同抗癌治疗。
Rational Design of a New Self-Codelivery System from Redox-Sensitive Camptothecin-Cytarabine Conjugate Assembly for Effectively Synergistic Anticancer Therapy.
机构信息
School of Pharmaceutical Science, Key Laboratory of Chemical Biology (Ministry of Education), Shandong University, 44 West Wenhua Road, Jinan, Shandong Province, 250012, P. R. China.
Key Lab of Colloid & Interface Chemistry (Ministry of Education), Shandong University, 250100, Jinan, P. R. China.
出版信息
Adv Healthc Mater. 2017 Dec;6(24). doi: 10.1002/adhm.201700829. Epub 2017 Oct 27.
Herein, two careful selected anticancer drugs camptothecin (CPT) and cytarabine (Ara-C) with different biological action mechanisms and different water solubility are conjugated together through a glutathione (GSH) cleavable disulfide bond to construct a redox-sensitive drug-drug conjugate, which can self-assemble into nanoparticles, thus notably improving the water solubility of CPT and the cell membrane permeability of Ara-C. Compared with free drugs, the self-assembled CPT-ss-Ara nanoparticles can concentrate in tumor tissues through the enhanced permeability and retention (EPR) effect, then they can be rapidly internalized by tumor cells and degrade into free drugs for killing the tumor cells when exposed to the reductive environment (GSH) of tumor cells, thereby reducing the injury to normal cells. Meanwhile, the CPT-ss-Ara nanoparticles can effectively protect CPT and Ara-C molecules from biological inactivation before their arrival in tumor microenvironment since free CPT and Ara-C are easy to partly lose their therapy efficacy due to their structure degradation in blood circulation. The in vitro and in vivo anticancer experimental results indicate that simultaneous release of free CPT and Ara-C can realize synergistic chemotherapy effects, thus markedly improve their anticancer activity. Therefore, our designed carrier-free, redox-sensitive CPT-ss-Ara nanoparticles might have promising clinical application to combat cancers.
在此,我们通过一个谷胱甘肽(GSH)可裂解的二硫键将两种经过精心挑选的具有不同生物学作用机制和不同水溶性的抗癌药物喜树碱(CPT)和阿糖胞苷(Ara-C)连接在一起,构建了一种具有氧化还原敏感性的药物 - 药物偶联物,它可以自组装成纳米颗粒,从而显著提高 CPT 的水溶性和 Ara-C 的细胞膜通透性。与游离药物相比,自组装的 CPT-ss-Ara 纳米颗粒可以通过增强的通透性和保留(EPR)效应聚集在肿瘤组织中,然后当暴露于肿瘤细胞的还原环境(GSH)时,它们可以被肿瘤细胞迅速内化并降解成游离药物以杀死肿瘤细胞,从而减少对正常细胞的损伤。同时,CPT-ss-Ara 纳米颗粒可以有效地保护 CPT 和 Ara-C 分子在到达肿瘤微环境之前免受生物失活的影响,因为游离的 CPT 和 Ara-C 由于在血液循环中结构降解,容易部分丧失其治疗效果。体外和体内抗癌实验结果表明,游离 CPT 和 Ara-C 的同时释放可以实现协同化疗作用,从而显著提高其抗癌活性。因此,我们设计的无载体、氧化还原敏感的 CPT-ss-Ara 纳米颗粒可能具有有前途的临床应用,以对抗癌症。